ADRENACLICK

Compare ADRENACLICK  to:
Compare
Compare

Generic Name for ADRENACLICK

Epinephrine 1mg/mL; 0.15mg/injection, 0.3mg/injection; auto-injection device; contains sulfites.

Legal Classification:

Rx

Pharmacological Class for ADRENACLICK

Sympathomimetic.

Manufacturer of ADRENACLICK

Sciele Pharma, Inc.

Indications for ADRENACLICK

Emergency treatment of anaphylaxis.

Adults and Children:

IM or SC inj into thigh. <15kg: not recommended. 15–30kg: 0.15mg. ≥30kg: 0.3mg.

Warnings/Precautions for ADRENACLICK

Cardiovascular disease. Hypertension. Hyperthyroidism. Diabetes. Parkinson's disease. Advise patient to seek medical help immediately. Train patient in use of device. Elderly. Pregnancy (Cat.C).

Interactions for ADRENACLICK

Potentiated by tricyclics, MAOIs, levothyroxine, antihistamines. Antagonized by β-blockers, α-blockers. Cardiac arrhythmias possible with concomitant digitalis, diuretics, antiarrhythmics. Pressor effects may be reversed by ergots, phenothiazines.

Adverse Reactions for ADRENACLICK

Tachycardia, palpitations, sweating, nausea, vomiting, respiratory difficulty, pallor, dizziness, weakness, tremor, headache, restlessness, anxiety, arrhythmia.

How is ADRENACLICK supplied?

Auto-injector syringe—1, 2

Related Disease:

Anaphylaxis~stimulants

Related Resources

FDA launches "Bad Ad Program" to detect misleading drug ads

May 11, 2010

The FDA's Division of Drug Marketing, Advertising, and Communications (DDMAC) has launched the Bad Ad Program, designed to educate healthcare providers about their role in ensuring that prescription drug advertising and promotion is truthful, and not misleading.

Adrenaclick Auto-injector launched for anaphylaxis

January 07, 2010

Sciele Pharma announced the availability of Adrenaclick (epinephrine injection auto-injector) for the emergency treatment of severe allergic reactions (Type I).

Needle-protected EpiPen and EpiPen Jr. Auto-Injector launched for anaphylaxis

October 26, 2009

DEY Pharma has launched re-designed EpiPen and EpiPen Jr. Auto-Injectors (epinephrine [1:1000]) that feature needle-protection, for no exposed needle, before and after use.

Promethazine injection gains boxed warning

September 16, 2009

The FDA has notified healthcare professionals that a Boxed Warning is being added to the prescribing information for promethazine hydrochloride products, describing the risks of severe tissue injury, including gangrene, requiring amputation following intravenous administration of promethazine.

New warnings for gadolinium-based contrast agents

September 09, 2010

The FDA is requiring that gadolinium-based contrast agents (GBCAs) carry new warnings on their labels about the risk of nephrogenic systemic fibrosis (NSF), a rare and potentially fatal condition, if the drug is administered to certain patients with kidney disease.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions